Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors

Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors : a Retrospective Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07413640

Acronym

MICRO-VAR

Enrollment

Registered

2026-02-17

Start date

2026-02-02

Completion date

2026-07-01

Last updated

2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Neoplasm

Brief summary

Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors. In clinical practice, the actual ablation volume often differs from the planned volume due to liver characteristics, vascular proximity, and tumor biology. This study aims to assess the variability between ablation small axis during percutaneous microwave ablation of liver lesions. The influence of patient-related (fibrosis, steatosis, portal flow) and tumor-related factors (location, histology, prior treatment) will be evaluated. Small axis and volume will be compared with volumes measured on immediate post-procedural CT and on CT/MRI at 6-12 weeks, accounting for expected tissue shrinkage.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Adult patients * Treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance * Adult treated for one or more liver lesions * Patients with available follow-up imaging

Exclusion criteria

* Two treatment cycles on the same lesion during the same session. * Reoperation on the same lesion. * Planned volume not available (no manufacturer data, not specified in the surgical report). * No control imaging injected between 1 and 4 months post-procedure. * Final ablation volume not measurable (e.g., artifacts, no injection on MRI). * No definitive diagnosis of the nature of the tumor on imaging and no histology available.

Design outcomes

Primary

Measure	Time frame	Description
Small final ablation axis measured on the post-procedure imaging modality considered to be the most reliable.	12 weeks	The final short axis will preferably be measured (in mm) on MRI at 6-12 weeks. If inter-patient variability in volume shrinkage exceeds 5%, the modality with the lowest relative variability (usually the immediate CT scan) will be used as the reference for estimating the final volume.

Countries

France

Contacts

CONTACTValérie LAURENT, MD-PhD

v.laurent@chru-nancy.fr33383157823

CONTACTAstrée LEMORE, MD

a.lemore@chru-nancy.fr33383157823

Outcome results